Comparative Pharmacology
Head-to-head clinical analysis: CARBIDOPA versus LODOSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBIDOPA versus LODOSYN.
CARBIDOPA vs LODOSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa availability to the brain.
Lodosyn (carbidopa) is a peripheral decarboxylase inhibitor that inhibits the conversion of levodopa to dopamine outside the central nervous system. By blocking aromatic L-amino acid decarboxylase (AAAD) in peripheral tissues, it increases the amount of levodopa available to cross the blood-brain barrier, enhancing central dopamine levels and reducing peripheral side effects such as nausea and vomiting.
Oral, 25 mg carbidopa with 100 mg levodopa (Sinemet 25/100) three times daily, titrated based on response. Maximum 200 mg carbidopa per day.
250 mg orally twice daily, in combination with levodopa/carbidopa.
None Documented
None Documented
Clinical Note
moderateCarbidopa + Droxidopa
"The therapeutic efficacy of Droxidopa can be decreased when used in combination with Carbidopa."
1-2 hours (terminal); clinically, coadministration with carbidopa does not alter levodopa half-life but reduces peripheral metabolism.
1.5–2.5 hours in adults; prolonged in renal impairment (up to 6–8 hours).
Renal: 70% as metabolites, 30% unchanged; biliary/fecal: minimal (<5%).
Renal: 70% unchanged; 30% as O-methylated and sulfate conjugates. Biliary/fecal: <5%.
Category A/B
Category C
Decarboxylase Inhibitor
Decarboxylase Inhibitor